Circumventricular organs are central nervous system brain sites thought to participate in neuroendocrine regulation of neural output. We have previously demonstrated a profound chronic hypotensive response to the angiotensin II (Ang II) AT 1 antagonist, losartan (10 mg/kg/day), in normal rats.
Introduction
The subfornical organ (SFO) is a circumventricular organ of the third ventricle. These unique brain regions lack the normal blood-brain-barrier and as such are thought to participate in neuroendocrine signalling pathways in the brain. 1, 2 It is now known that circulating substances like angiotensin II (Ang II) can act at the SFO to modulate cardiovascular function. 3, 4 Intravenous Ang II can cause a pressor response that is blocked by prior lesion of the SFO. 5 Through its projections to the paraventricular nucleus, the SFO is thought to participate in central sympathetic nervous system regulation. 6 It has been shown that paraventricular neurones activated by the SFO project to the rostral ventral lateral medulla, the brain region that is thought to be the central site of sympathetic nervous system activity. 7, 8 We have shown a role of another circumventricular organ, the area postrema, in the chronic hypotensive response to the AT 1 -receptor antagonist, losartan, in normal rats. 9 We demonstrated that chronic treatment with losartan (10 mg/ kg/day) in normal rats consuming a normal salt diet produced a fall in mean arterial pressure of nearly 35 mmHg after 10 days. 9 In rats with lesions of the area postrema, the long-term steady state depressor response to losartan was attenuated by nearly 40%, 10 suggesting this brain stem region as an important target site for AT 1 -receptor antagonists.
We still do not fully understand the mechanism of this profound hypotensive response to losartan in normal rats. It does not appear to be mediated through blockade of the peripheral vasoconstrictor effects or renal actions of Ang II. 10, 11 Furthermore, the mechanism of action does not appear to be mediated through increased levels of Ang II acting at AT 2 -receptors. 12 The SFO is rich in AT 1 -receptors and has been shown to mediate actions of Ang II. 13, 14 It seems reasonable that this circumventricular organ could be playing a role in the hypotensive effects of long-term losartan treatment as well. In order to test this hypothesis, mean arterial pressure responses were measured in sham rats and rats with lesions of the SFO treated with losartan (10 mg/kg/day) for nine days. In this study, we measured 12-hour (day/night) pressure averages in order to characterise the day/night profile of the arterial pressure responses to losartan.
Materials and methods
Adult male Sprague-Dawley rats (275-300 g) were used in all experiments. All procedures were conducted in accordance with institutional and National Institutes of Health guidelines.
Surgical procedures
Adult male Sprague-Dawley rats were randomly selected for either lesion of the SFO (SFOx) or sham operation. Rats were pre-anaesthetised with pentobarbital (32.5 mg/kg, i.p.) and atropine (0.2 mg/kg i.p.). Surgical anaesthesia was achieved with an intramuscular injection containing a cocktail of anaesthetic agents (acetylpromazine, 0.2 mg/kg; 15 Briefly, a dorsal midline incision was made through the skin of the skull. Bregma and lambda landmarks were exposed and a 3 mm hole was made in the skull 0.8 mm posterior to bregma. A Teflon-insulated monopolar tungsten electrode was lowered to four predetermined coordinates for the location of the SFO, and a current of 1 mA was passed for 7 seconds. Sham operations were identical to lesions, with the exception that ventral coordinates were 1.5 mm less so as to not damage the SFO, and no current was passed. The hole in the skull was repaired with bone wax and the skin was closed with 3-0 silk suture. After surgery, all rats were given an intramuscular antibiotic injection of 2.5 mg gentamycin and a subcutaneous injection of 0.075 mg butorphanol tartrate for analgesic purposes. One week later the rats were instrumented with radio telemetry blood pressure (BP) transducers, and both femoral and jugular venous catheters. The telemetry unit consists of a fluid-filled catheter attached to a transducer/transmitter. A midline abdominal incision was made to expose the descending aorta. After clamping the aorta proximally, the catheter was implanted directly into the aorta via a 21-gauge needle. The catheter was advanced cranially so the tip was located just distal to the renal arteries. The catheter was glued in place with medical adhesive and the aortic clamp was removed. The body of the transmitter was secured to the abdominal wall during closure of the body cavity with 3-0 silk suture. The skin was closed with surgical staples. Rats were then instrumented with femoral and jugular venous catheters. The catheters were tunneled subcutaneously and exited between the scapulae. The catheters were passed through a flexible spring connected to a single channel hydraulic swivel to which the femoral venous catheter was attached. The springs were attached to the rats via a rubber harnesses (Harvard Apparatus), which the rats wore for the remainder of the protocol. After surgery, all rats were given antibiotic and analgesic injections as described above. During the first three days of post-surgery recovery, the rats received daily prophylactic intravenous antibiotics (ampicillin, 15 mg). The rats were also started on a continuous intravenous infusion of sterile 0.9% saline (7 ml/ 24-hour). The rats were housed individually in metabolic cages. A 0.4% NaCl diet (Research Diets) and distilled water were provided ad libitum. Rats were allowed one week to recover before entering the experimental protocol.
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Experimental protocol
The first three days of the protocol served as a control period, in which the rats received a continuous intravenous infusion of 0.9% sterile saline (7 ml/24-hour). This was followed by a nine-day infusion of the AT 1 -receptor antagonist, losartan (10 mg/kg/day). The losartan was dissolved in 0.9% sterile saline and infused at a rate of 7 ml/ 24 hours. A final recovery period of three to four days, identical to the control period, completed the protocol. The infusions were administered via a 0.2 µm syringe filter.
Twelve-hour measurements (beginning at 7:00 a.m. corresponding to lights on) of mean arterial pressure (MAP) and heart rate were made via the data acquisition system. Daily measurements of food intake, water intake, urine output and urinary sodium were recorded in conscious, unrestrained rats in their home cages. MAP and heart rate were measured continuously by radiotelemetric pressure transducers (Model #TA11PA-C40, Data Sciences International,Inc.) at a sampling rate of 500 Hz for 10 seconds each minute. Twenty-four hour food and water intake, as well as urinary output, were measured gravimetrically. Sodium intake was calculated as the sum of sodium received in the daily infusion (1 mmol/day i.v.), plus the product of food intake and sodium content of the food, (0.4% NaCl, 0.07 mmol/g). Urinary sodium content was measured with an ion-specific electrode (Nova Biomedical). Urinary sodium excretion was calculated as the product of urine flow rate and urinary sodium concentration. The protocol was conducted in both previously described groups: 1) SFOx (n=10), and 2) SHAM rats (n=8).
Measurement of baseline plasma renin activity and tests of AT 1 -receptor blockade
Plasma renin activity (PRA) was measured in rats on the second control day. Blood (500 µl) was collected via the jugular catheter and placed into a chilled 1-ml syringe containing 1 mg EDTA in 20 µl. The whole blood was centrifuged, and plasma was collected and stored at -70ºC for later radioimmunoassay, as previously described. 16 To test the efficacy of the AT 1 -receptor blockade, acute pressor responses to bolus injections of Ang II (30 ng i.v.) were measured on day 3 of the control period and day 7 of the losartan infusion. Responses were measured as the peak increase of arterial pressure.
Functional testing of lesion of the subfornical organ
To assess the functional presence of the subfornical organ, we performed a drinking response test to an infusion of Ang II. It has been previously reported that normal rats will respond by drinking approximately 2-4 ml of water in response to a slow infusion of Ang II over 90 minutes and this response is significantly attenuated in animals with lesions of the SFO. 17 On control day 3, all rats were infused with Ang II at a rate of 1.8 µg/hour for 90 minutes.Water intake was measured during this time in all rats.
Histological verification of SFOx
On completion of the protocol, all rats were anaesthetised as described above and perfused intracardially with 4% paraformaldehyde. Whole brains were dissected and soaked in 4% paraformaldehyde for two days. The brains were then transferred to 208 PAPER 
Results
Functional testing of lesion of the subfornical organ and histological verification of SFOx
On control day 3, water intake responses to a slow infusion of Ang II (30 ng/minute for 90 minutes) were measured in sham and SFOx rats. Sham rats drank 2.7+0.8 ml,while SFOx rats only drank 1.0+0.2 ml of water. These results were statistically different (p<0.05). Histological verification of SFO lesion was confirmed in all SFOx rats. Only rats with complete lesions of the SFO were included in the study. Typical examples of a sham lesion (A) and SFO lesion (B) are shown in Figure 1 . In addition, SFOx rats were only included in the study if there was minimal destruction of the adjacent tissue at the light microscopic level.
Plasma renin activity levels and tests of AT 1 -receptor blockade
PRA was measured as described in all rats on the second control day. PRA was not different between the groups (SFOx, 7.0+1.2 ng Ang I/ ml/hour; SHAM 6.1+0.9 ng Ang I/ml/hour).
The efficacy of AT 1 -receptor blockade was assessed by measuring the pressor responses to 30 ng of Ang II on the third control day and day 7 of losartan treatment. Control responses were similar in sham (+55+5 mmHg) and SFOx (+60+2 mmHg) rats. This response was abolished (0+0 mmHg) on day 7 of losartan treatment in both groups. Figure 2 (A) demonstrates the MAP responses to losartan in SFOx and sham rats throughout the protocol. The shaded areas represent the 12-hour average MAP during the lights off (night-time) periods, whereas the light areas represent 12-hour averages of MAP during the lights on (daytime) hours. There were no significant differences observed between basal MAP in SFOx and sham rats during the initial three-day control period (SFOx: 102+2 mmHg; SHAM: 99+3 mmHg). Sham rats demonstrated a significantly faster fall in MAP during the initial 12 hours of losartan treatment. Thereafter, MAP dropped continuously during the first 36 hours of losartan treatment in both groups before establishing a circadian rhythm. MAP continued to decrease in both groups before reaching a steady-state pattern on approximately day 7 of losartan treatment. The average day and night MAP was lower in SHAM rats throughout the losartan treatment. This attenuated hypotensive response to losartan in SFOx rats was statistically significant during the night-time hours on day 5 and days 7-9. By day 7 of losartan treatment, night-time average MAP had decreased to 75+2 mmHg in sham rats and to only 83+2 mmHg in SFOx rats. This trend continued through day 9 of losartan treatment. Throughout the recovery period, both groups of rats demonstrated similar increasing levels of MAP, The heart rate responses to losartan are shown in Figure 2 (B) . The shaded areas represent the 12hour average heart rate during the lights off (night-time) periods, whereas the light areas represent 12-hour averages of heart rate during the lights on (daytime) hours. The three-day average control heart rate was 428+6 beats/minute in sham rats and 410+12 beats/minute in SFOx rats. SFOx rats tended to have lower heart rates throughout losartan treatment and this was more pronounced during the night-time hours, although there were no statistically significant differences seen between heart rates in both groups throughout the protocol.
Arterial pressure and heart rate responses to losartan
Cumulative sodium and water balance
Cumulative water balance data is shown in Figure  3 (A). The three-day average control water intake was 20+2 ml/day in sham rats and 19+2 ml/day in SFOx rats. There were no differences in water balance observed between the groups throughout the protocol.
Cumulative sodium balance data is shown in Figure 3 (B) . The three-day average control sodium intake was not different between the groups (SHAM: 2.4+0.1 mEq/day; SFOx: 2.5+0.1 mEq/ day). Throughout losartan treatment, a lower cumulative sodium balance was observed in SFOx rats. This difference was statistically significant on days 7-9 of losartan treatment and throughout the recovery period. By day 9 of losartan treatment, sham rats had a cumulative sodium balance of 6.0+0.2 mEq, in contrast to 3.3+0.8 mEq in SFOx rats.
Discussion
There were three major findings in this study. First, lesion of the subfornical organ did not alter basal BP in these animals. Secondly, subfornical organ lesioned rats demonstrated an attenuated hypotensive response to chronic losartan treatment that was more pronounced during the nighttime hours. Lastly, subfornical organ lesioned animals retained less sodium chronically than sham rats during the course of losartan treatment.
We have previously demonstrated a profound long-term hypotensive response to chronic losartan treatment in normal rats. 10 Because of the numerous actions of Ang II, the mechanisms of action of this response to AT 1 -receptor blockade are complex. We do not believe that blockade of peripheral vasoconstrictor effects of Ang II is solely responsible for this response. Certainly, we have demonstrated that, at this dose of losartan, the acute vasoconstrictor effects of Ang II are blocked, but others have shown that a lower dose of losartan (1 mg/kg/day) blocks the acute vasoconstrictor effects of Ang II but has no chronic lowering effect on BP. 11 This is in agreement with studies demonstrating that chronic Ang II hypertension is not due solely to Ang II peripheral vasoconstriction, but rather to a slower developing neurally-mediated sympathoexcitation. 18 In addition, it is possible that blockade of renal AT 1 -receptors could contribute to this long-term hypotensive response to losartan. The fact that we did not observe any significant changes in daily sodium and water excretion in losartan-treated animals despite a significant decrease in arterial pressure minimises this possibility.
In the present study, we have demonstrated an attenuated response to the chronic hypotensive effects of losartan in SFO lesioned rats compared with normal animals. Indeed, Ang II has been shown to modulate BP through actions at the SFO. 5, 19 The efferent projections of the SFO and connections to the rostral ventral lateral medulla (RVLM) would suggest that this is mediated through the sympathetic nervous system. 7, 8, 20 It seems probable that endogenous Ang II could also act through the SFO to maintain arterial pressure. Our results support this idea, in that the SFO is partially responsible for mediating the hypotensive effects of blockade of endogenous Ang II. Certainly, other central nervous system sites have been implicated in the actions of Ang II and, as such, could be mediating part of the hypotensive effects of losartan as well. We have demonstrated that the area postrema, another circumventricular organ responsible for actions of Ang II, 21, 22 plays a role in this response. 9, 10 Similar to the present study, area postrema lesioned animals demonstrated a significantly attenuated hypotensive response to losartan. 10, 23 Lastly, since losartan can cross the blood-brain-barrier, 23 the mechanism of this response could involve blockade of AT 1 -receptors in other central sites, such as the RVLM, which has been shown to mediate hypotensive effects to AT 1receptor blockade. 24 On the other hand, it is possible that non-AT 1receptor mediated events may be contributing to the chronic hypotensive response to AT 1 -receptor blockade. The AT 2 -receptor is thought to mediate opposing actions of Ang II at AT 1 -receptors. 25, 26 Therefore, increased levels of Ang II during losartan treatment acting unopposed at AT 2 -receptors could contribute to this chronic hypotensive response. Studies from our laboratory do not support this idea in this model. When the AT 2receptor antagonist, PD 123319, was simultaneously infused with losartan, we saw no attenuation in the BP-lowering effect of chronic losartan treatment. 12 These results suggest that the AT 2 -receptor is not involved in mediating the chronic hypotensive effects of losartan in normal rats.
In addition, it is possible that certain Ang II fragments or metabolites could be playing a role in this response. There is much recent evidence that Ang-(1-7) possesses vasodilatory properties and is an important active element in the reninangiotensin system. 27, 28 Therefore, it is thought that rising levels of Ang-(1-7) during angiotensinconverting enzyme (ACE) inhibitor treatment may be contributing to the antihypertensive effects of these compounds. 29, 30 The same concept could be true during AT 1 -receptor blockade treatment. Ang-(1-7) levels have been shown to be elevated during AT 1 -receptor antagonist treatment. 31 Indeed, recent studies from our laboratory support this concept. We have demonstrated that when the Ang-(1-7) antagonist, A-779, was infused simultaneously with losartan, the chronic hypotensive effects of losartan were attenuated by about a third by day 7 of treatment. 32 These results support the idea that Ang-(1-7) may be involved in mediating part of the chronic hypotensive effects of losartan. This potential mechanism of action would also explain the fact that the lesion of the subfornical organ itself did not alter baseline levels of arterial pressure.
In this study, we demonstrated an overall lower cumulative sodium balance in SFO lesioned rats treated with losartan, compared with sham-operated controls. Interestingly, cumulative water balance was not different between the two groups. We do not know if this was an effect of the lesion, or the combination of the lesion and the losartan treatment. Furthermore, we did not observe any significant daily differences between the groups in sodium intake or excretion. The SFO has been implicated in sodium intake, 33, 34 but has also been implicated in sodium excretion. 35 For example, the SFO has been shown to mediate sodium appetite during sodium depletion. 34 Furthermore, SFO lesion attenuates the natriuretic response to volume loading 36 and alters sodium excretion during ACE inhibition. 35 Careful inspection of our data would suggest that the overall lower cumulative sodium balance seen was due to the fact that SFO lesioned animals had slightly lower daily sodium intakes than sham controls and this was detected because of the chronic nature of these studies. This would suggest that the SFO does participate in the sodium appetite in normal rats consuming a normal sodium diet. Again, we cannot rule out the possibility that the combination of the lesion and losartan treatment, played a role in this observation. This does not seem likely, owing to the fact that losartan-treated sham rats did have differing cumulative sodium balances.
In summary, we have demonstrated an attenuated chronic hypotensive response to losartan in SFO lesioned rats. We conclude that the SFO mediates the chronic BP-lowering effects of this compound in normotensive, salt-replete rats. Furthermore, we have demonstrated that SFO lesioned rats maintained chronic lower cumulative sodium balances than sham-operated controls, thus re-affirming the role of this circumventricular organ in sodium homeostasis.
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